# A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)

> **NCT04524871** · PHASE1,PHASE2 · RECRUITING · sponsor: **Hoffmann-La Roche** · enrollment: 518 (estimated)

## Conditions studied

- Advanced Liver Cancers

## Interventions

- **DRUG:** Atezolizumab
- **DRUG:** Bevacizumab 15 mg/kg
- **DRUG:** Tiragolumab
- **DRUG:** Tocilizumab
- **DRUG:** TPST-1120
- **DRUG:** Tobemstomig 2100 mg
- **DRUG:** Bevacizumab 10 mg/kg
- **DRUG:** Tobemstomig 600 mg
- **DRUG:** Tobemstomig 1200 mg
- **DRUG:** ADG126
- **DRUG:** IO-108 1800 mg
- **DRUG:** NKT2152
- **DRUG:** IO-108 1200 mg

## Key facts

- **NCT ID:** NCT04524871
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-11-01
- **Primary completion:** 2027-07-30
- **Final completion:** 2027-09-30
- **Target enrollment:** 518 (ESTIMATED)
- **Last updated:** 2026-04-23

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04524871

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04524871, "A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04524871. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*